Tag: lymphoma cancer

Dr. Sarah Rutherford Describes Recently Opened Trial for Selinexor and RICE Chemotherapy in relapsed/refractory DLBCL

In this video Dr. Sarah Rutherford discusses a trial for men and women with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), who were not cured by initial treatment with R-CHOP or a similar chemotherapy.

The purpose of this study is to determine the maximum tolerated dose of selinexor when given in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) in patients with relapsed or refractory aggressive B-cell lymphomas. This is an open-label, phase 1 trial with a standard dose escalation schema.

Tumor biopsies and peripheral blood will be taken pre- and post-treatment with selinexor to examine the study’s biologic objectives.

Key Eligibility

  • Men and woman greater than or equal to 18 years of age
  • Confirmed diffuse large B-cell lymphoma, double/triple hit lymphoma, indolent lymphomas transformed to DLBCL or other aggressive B-cell lymphoma, and follicular lymphoma grade 3B
  • Treatment with at least two cycles of one prior anthracycline-based regimen administered with curative intent
  • Detailed eligiblity reviewed when you contact the study team

If you’re interested in participating in this trial please call 212-746-2919 for more information. A full listing of DLBCL trials at Weill Cornell Medicine can be found on our clinical trials listing.

Dr. Peter Martin Describes a Copanlisib Trial for Mantle Cell Lymphoma Patients who have Previously Failed Ibrutinib Treatment

In this video Dr. Peter Martin describes the benefits of a recently opened clinical trial evaluating the efficacy and safety of copanlisib for mantle cell lymphoma (MCL) patients, who have failed or were unable to tolerate ibrutinib treatment. The purpose of this study is to to evaluate the efficacy and safety of copanlisib monotherapy in patients with MCL.

If you’re interested in participating in this trial please call 212-746-2919 for more information. A full listing of MCL trials at Weill Cornell Medicine can be found here.

Dr. John Leonard Discusses the Top Lymphoma Studies from ASH15

In this video from Targeted Oncology, Lymphoma Program Director, Dr. John Leonard discusses the top lymphoma studies presented during the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

In addition to this video, Dr. Leonard also continued his now annual tradition of picking 10 noteworthy lymphoma abstracts released before the meeting in his #LeonardList. As he explained the criteria for picking abstracts on the list:

“I scan all the lymphoma-related abstracts, focusing less on the biology and more on the therapy. I look at both oral and poster abstracts because I think people might miss posters that are of interest and worth highlighting. And I focus on ideas I think are either practice changing, or intriguing, or ‘out of the box,’ that people might otherwise not see.”